https://www.lucintel.com/transarterial-chemoembolization-market.aspx

According to a market report by Lucintel, the future of the global transarterial chemoembolization market looks promising with opportunities in the hospital, clinic, and cancer research center markets. The global transarterial chemoembolization market is expected to reach an estimated $24.1 billion by 2030 with a CAGR of 5.7% from 2024 to 2030. The major drivers for this market are increasing incidence of liver cancer, continuous advancements in TACE techniques and technology, and growing demand for minimally invasive cancer treatments.

A more than 150 — page report is developed to understand Trends, opportunity and forecast in transarterial chemoembolization market to 2030 by product type (chemotherapeutic agents, radio therapeutic agents, and drug-eluting particles), procedure type (conventional TACE and DEB-TACE), indication (unresectable HCC and early-stage HCC), end use (hospitals, clinics, cancer research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).

In this market, chemotherapeutic agent, radio therapeutic agent, and drug-eluting particle are the major segments of transarterial chemoembolization market by product type. Lucintel forecasts that drug-eluting particle is expected to witness highest growth over the forecast period.

Within this market, hospital is expected to witness highest growth over the forecast period.

Download sample by clicking on transarterial chemoembolization market

North America is expected to witness highest growth over the forecast period.

Novartis, Nippon Kayaku, Pfizer, Spectrum Pharmaceuticals, Celgene, Siemens Healthcare, Bayer, Merck, Cook, and F. Hoffmann-La Roche are the major suppliers in the transarterial chemoembolization market.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1–972–636–5056 or write us at helpdesk@lucintel.com

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
 Roy Almaguer
 Lucintel
 Dallas, Texas, USA
 Email: roy.almaguer@lucintel.com 
 Tel. +1 972.636.5056

Explore Our Latest Publications

Carbon Brush Market in Canada

Turbo Expanders Market in Canada

Dental Imaging Market in Canada

Gaucher Disease Market in Canada

Magnetic Resonance Imaging Market in Canada

Mobile Imaging Services Market in Canada